Read more.
Valeant sells the rights to its aesthetic injectables to Nestle, while Allergan touts physician support and challenges Valeant's business model. In this week's edition of DermWireTV, learn about Valeant's latest offer for Allergan, see Provectus ring the opening bell on the NYSE, and get the scoop on myoscience's latest award." />

ModernAesthetics.tv / Aesthetics

DermwireTV — Valeant Ups Allergan Bid, Nestle Buys Injectables, and Allergan Makes Its Case

BREAKING NEWS: Valeant has increased its offer for Allergan to $72 per share. Read more.
Valeant sells the rights to its aesthetic injectables to Nestle, while Allergan touts physician support and challenges Valeant's business model. In this week's edition of DermWireTV, learn about Valeant's latest offer for Allergan, see Provectus ring the opening bell on the NYSE, and get the scoop on myoscience's latest award.

12395 video views since 5/30/2014